These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 9198009)
1. Single and repeated intravenous toxicity studies of pamiteplase (genetical recombination) in rats and monkeys. Ishikawa A; Ohata T; Imamura K; Iwasaki M; Sakai T; Matsuzawa T; Okazaki S J Toxicol Sci; 1997 May; 22(2):117-33. PubMed ID: 9198009 [TBL] [Abstract][Full Text] [Related]
2. Reproductive toxicity, mutagenicity and antigenicity of pamiteplase (genetical recombination). Ishikawa A; Fujiwara M; Ohata T; Wakata A; Hoshino K; Matsuzawa T; Barrow PC; Shimazu H; Ono C; Putman DL; San RH; Couch RC J Toxicol Sci; 1997 Aug; 22(3):207-17. PubMed ID: 9279823 [TBL] [Abstract][Full Text] [Related]
3. Thrombolytic activity of YM866, a novel modified tissue-type plasminogen activator, in a photochemically induced platelet-rich thrombosis model. Kawasaki T; Kaku S; Takenaka T; Yanagi K; Ohshima N J Cardiovasc Pharmacol; 1994 Jun; 23(6):884-9. PubMed ID: 7523779 [TBL] [Abstract][Full Text] [Related]
4. Thrombolysis with intracoronary administration of YM866, a novel modified tissue-type plasminogen activator, in a canine model of coronary artery thrombosis. Kawasaki T; Katoh M; Kaku S; Gushima H; Takenaka T; Yui Y; Kawai C Jpn J Pharmacol; 1993 Nov; 63(3):319-25. PubMed ID: 8107325 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic properties of a novel tissue-type plasminogen activator pamiteplase after single intravenous administration to rats, dogs, and monkeys. Oikawa K; Kamimura H; Watanabe T; Miyamoto I; Higuchi S Thromb Res; 2001 Mar; 101(6):493-500. PubMed ID: 11323007 [TBL] [Abstract][Full Text] [Related]
6. Thrombolytic activity of a novel modified tissue-type plasminogen activator, YM866, in a canine model of coronary artery thrombosis. Kawasaki T; Katoh M; Kaku S; Gushima H; Takenaka T; Yui Y; Kawai C Jpn J Pharmacol; 1993 Sep; 63(1):9-16. PubMed ID: 8271535 [TBL] [Abstract][Full Text] [Related]
7. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289 [TBL] [Abstract][Full Text] [Related]
8. Experimental model of carotid artery thrombosis in rats and the thrombolytic activity of YM866, a novel modified tissue-type plasminogen activator. Kawasaki T; Kawamura S; Katoh S; Takenaka T Jpn J Pharmacol; 1993 Oct; 63(2):135-42. PubMed ID: 8283822 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys. Henry SP; Bolte H; Auletta C; Kornbrust DJ Toxicology; 1997 Jun; 120(2):145-55. PubMed ID: 9184201 [TBL] [Abstract][Full Text] [Related]
10. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928 [TBL] [Abstract][Full Text] [Related]
11. NTP Toxicology and Carcinogenesis Studies of p-Nitrobenzoic Acid (CAS No. 62-23-7) in F344/N Rats and B6C3F1 Mice (Feed Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1994 Dec; 442():1-306. PubMed ID: 12595921 [TBL] [Abstract][Full Text] [Related]
12. Species specificity in the blood cholesterol-lowering effect of YM-16638. Goto S; Shimokawa T; Ugawa T; Hisamichi N; Masuyama Y; Iizumi Y; Sato N; Takenaka T; Kodama T Br J Pharmacol; 1996 May; 118(1):174-8. PubMed ID: 8733592 [TBL] [Abstract][Full Text] [Related]
13. [Single dose intravenous toxicity studies of T-3762, a novel parenteral quinolone antimicrobial agent, in rats, dogs and monkeys]. Nagai A; Shibata T; Nagasawa M; Shiotani N; Miyazaki M; Kawamura Y; Kodama T; Onimaru T Jpn J Antibiot; 1998 Oct; 51(10):583-99. PubMed ID: 9914950 [TBL] [Abstract][Full Text] [Related]
14. [Research and development of novel modified tissue-type plasminogen activator (t-PA), pamiteplase]. Katoh M; Hayamizu K Nihon Yakurigaku Zasshi; 2000 Apr; 115(4):237-43. PubMed ID: 10876808 [TBL] [Abstract][Full Text] [Related]
15. Clinical pathologic alterations associated with subcutaneous administration of recombinant human interleukin-4 to cynomolgus monkeys. Gossett KA; Barbolt TA; Cornacoff JB; Zelinger DJ; Dean JH Toxicol Pathol; 1993; 21(1):46-53. PubMed ID: 8378706 [TBL] [Abstract][Full Text] [Related]
16. Comparison of drug disposition between wild-type and novel tissue-type plasminogen activator pamiteplase in rats. Oikawa K; Watanabe T; Higuchi S Drug Metab Dispos; 2000 Sep; 28(9):1087-93. PubMed ID: 10950854 [TBL] [Abstract][Full Text] [Related]
17. Effects of recombinant human interleukin 6 (rhIL-6) in marmosets (Callithrix jacchus). 1. General toxicity and hematological changes. Klug S; Neubert R; Stahlmann R; Thiel R; Ryffel B; Car BD; Neubert D Arch Toxicol; 1994; 68(10):619-31. PubMed ID: 7857201 [TBL] [Abstract][Full Text] [Related]
18. Comparative study of a mutant tissue-type plasminogen activator, YM866, with a tissue-type plasminogen activator in a canine model of femoral arterial thrombosis. Kawasaki T; Kaku S; Sakai Y; Takenaka T J Pharm Pharmacol; 1996 Oct; 48(10):1041-8. PubMed ID: 8953506 [TBL] [Abstract][Full Text] [Related]
19. NTP Toxicology and Carcinogenesis Studies of 3,4-Dihydrocoumarin (CAS No. 119-84-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1993 Sep; 423():1-336. PubMed ID: 12616288 [TBL] [Abstract][Full Text] [Related]
20. Toxicology and carcinogenesis studies of diisopropylcarbodiimide (Cas No. 693-13-0) in F344/N rats and B6C3F1 mice (dermal studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 2007 Feb; (523):1-286. PubMed ID: 17554397 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]